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Abstract 
Background: Combination chemotherapy with mitomycin C and methotrexate (MM) was reported to be effective 
for 24% of patients with metastatic breast cancer (MBC) who had been treated with anthracycline and taxane. Anti-
metabolites such as capecitabine and antitubulins such as vinorelbine have been generally used for MBC treatment 
after anthracycline and taxane. A subsequent choice of chemotherapy should be offered to patients with MBC who 
have kept good performance status (PS) after being aggressively treated with anthracycline, taxane, capecitabine, and 
vinorelbine (ATCV), but is not well clear which treatment is superior to others after ATCV. In this study, we examined 
whether MM treatment is a good choice following ATCV.
Methods: We retrospectively reviewed the medical records of 31 patients with HER2-negative metastatic breast 
cancer who were treated with MM following ATCV. One cycle of MM was defined as MMC 8 mg/m2 on day 1 and MTX 
60 mg/m2 on day 1 and day 15, administered intravenously every 4 weeks.
Results: Response rate and clinical benefit rate were 9.7 and 19.4%, respectively. Median times to progression and 
times to failure were 3.9 and 3.7 months, respectively. Adverse events of grade 3 and/or 4 were observed in 36% 
patients. Thrombocytopenia of grade 3 or 4 was 12.9 and 3.2%. Grades 3 and 4 of leucopenia and anemia were 12.9 
and 9.7%, respectively.
Conclusion: MM is effective and tolerable for MBC patients even after aggressive treatment with ATCV. MM is one 
treatment choice when patients have kept good PS and bone marrow function even after multiple regimens of 
chemotherapy.
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Background
Treatment for breast cancer generally has two aspects. 
One is surgery for local control; the other is systemic 
treatment to limit or eliminate potentially metastatic 
disease. Sequential administration of anthracycline and 
taxane is recommended as systemic chemotherapy in 
neo-adjuvant or adjuvant settings, depending on risk fac-
tors such as metastasis in axillary lymph nodes. Once 
metastatic breast cancer (MBC) has been diagnosed with 
radiological or imaging assessments, it is very difficult to 
achieve complete eradication of MBC while maintaining 
both the length and the quality of patients’ lives.
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Cytotoxic drugs playing major roles in treating MBC 
include antitubulins such as vinorelbine and eribulin, 
antimetabolites such as fluorouracil derivatives, capecit-
abine or S-1, and gemcitabine.
With vinorelbine, the recurrence rate (RR) for 
advanced or recurrent breast cancer previously treated 
with anthracycline and taxane was 20–25% (Toi et  al. 
2005; Livingston et al. 1997; Zelek et al. 2001), and TTP 
was 91–115 days (Toi et al. 2005; Livingston et al. 1997).
With eribulin for locally recurrent or metastatic 
HER2 negative breast cancer, RR was 13–29%, CBR was 
23–52%, and the median progression-free survival (PFS) 
was 3.7–6.8  months (McIntyre et  al. 2014; Aogi et  al. 
2012; Cortes et al. 2011).
With Capecitabine for MBC patients who had failed 
with a regimen containing anthracycline and taxane, 
median RR was 23.6% (15–29%). Median TTP was 
96.7  days (89–107  days) (Blum et  al. 1999; Blum and 
Dieras 2001; Reichardt et al. 2003; Fumoleau et al. 2004; 
Wist et al. 2004).
In S-1 for 35 MBC patients pretreated with anthracy-
cline, taxane, and capecitabine, RR was 3%, and the clini-
cal benefit rate (CBR) was 20%. TTF was 2.8 months (Ito 
et al. 2009).
Although MBC can be resistant to treatments that 
include anthracycline, taxane, capecitabine, and vinorel-
bine, a substantial number of patients have kept good 
performance status (PS). Such patients are eager for the 
next effective treatment to keep their MBC under control 
and to maintain their quality of life.
We previously reported that the combination ther-
apy of MMC and MTX (MM) was effective for MBC 
patients pretreated with anthracycline and taxane (Tan-
abe et  al. 2009). Partial response (PR) was observed in 
24% patients, and TTP was 4.8 months. We hypothesized 
that this combination treatment would have the potential 
to control MBC in appropriately selected patients. When 
PS is good even after anthracycline, taxane, capecitabine, 
and vinorelbine, patients may be able to tolerate subse-
quent chemotherapy.
Here, we report a retrospective analysis of the activ-
ity of MMC and MTX for HER2-negative patients with 
MBC who had been treated with ATCV.
Methods
Patients
We reviewed the medical records of patients whose MBC 
had been treated with MM from September 2005 to July 
2007 at a Cancer Institute Hospital. The eligibility criteria 
were as follows: (1) clinically and histologically confirmed 
MBC; (2) prior treatment with anthracycline, taxane, 
capecitabine, and vinorelbine; (3) absolute neutrophil 
count >1,500 μL; (4) transaminase <2.5 × UNL (in case 
of hepatic metastasis, <5 ×  UNL); (5) serum creatinine 
<1.5  ×  UNL; (6) measurable lesion(s) according to the 
Response Evaluation Criteria in Solid Tumor (RECIST) 
guidelines Ver.1.1; (7) performance status of 0 or 1 based 
on the Eastern Cooperative Oncology Group scale; (8) 
written informed consent from each patient.
Administration schedule of MM
MMC 8  mg/m2 was intravenously given on day 1 and 
MTX 60 mg/m2 on day 1 and day 15 every 4 weeks. After 
MMC reached a cumulative dose of 50 mg/m2, only MTX 
of 60 mg/m2 on day 1 and day 15 was repeated until pro-
gressive disease (PD) or adverse events were observed.
When hematological toxicity of grade 3 or 4 was 
observed, dosage was reduced by 20% in the next treat-
ment. When hematological or other toxicity was grade 
2 or 3, the treatment date was postponed for 1 week or 
more until patients recovered from the toxicity. When 
the performance status became worse than grade 3, the 
treatment was stopped and changed. Adverse events were 
graded by Common Terminology Criteria for Adverse 
Events (CTCAE) v3.0. Symptomatic adverse events were 
evaluated based on questionnaires filled out by patients 
when they visited our hospital and confirmed by the phy-
sician’s interview and medical examination.
Evaluation of efficacy and safety
All patients were followed up with hematological find-
ings, chest-abdominal CT, bone scintigraphy, and ultra-
sonography according to metastatic sites.
Responses were assessed according to the RECIST 
v1.1. Complete response (CR): Disappearance of all tar-
get lesions. Any pathological lymph node (whether tar-
get or non-target) must have reduction in the short axis 
to <10 mm. Partial response: At least a 30% decrease in 
the sum of diameters of target lesions, taking as a refer-
ence the baseline sum diameters. Progressive disease: 
At least a 20% increase in the sum of diameters of target 
lesions, taking as a reference the smallest sum while in 
the study (including the baseline sum if that is the small-
est). In addition to the relative increase of 20%, the sum 
must also demonstrate an absolute increase of at least 
5 mm. The appearance of one or more new lesions is also 
considered progression. Stable disease (SD): Neither suf-
ficient shrinkage to qualify for PR nor sufficient increase 
to qualify for PD, taking as a reference the smallest sum 
diameters while in the study (Eisenhauer et  al. 2009). 
Objective response rate (ORR) was defined as the sum of 
the CR and PR rates; CBR was defined as the sum of the 
CR, PR, and long SD rates. TTP was defined as the period 
from the beginning of the first cycle of MM treatment to 
PD, and TTF was defined as the period from the initial 
MM treatment to its discontinuation because of PD or 
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unacceptable toxicity. All adverse events and laboratory 
parameters were graded according to CTCAE v 3.0.
Statistical analysis
TTP and TTF were calculated by the Kaplan–Meier 
method, using SPSS ver. 17. (IBM, Japan).
Results
Patient characteristics
The patients’ characteristics are shown in Table 1. Thirty-
one patients received MM between September 2005 and 
July 2007. Their median age was 53 years (range 30–75). 
All patients were Japanese; 30 were female and one was 
male. Twenty-nine patients (93.5%) had a performance 
status score of 0. Fifteen patients (48.4%) were positive 
for both of estrogen receptor (ER) and progesterone 
receptor (PgR), six (19.4%) were ER positive and PgR 
negative, and 10 (32.3%) were negative for both. Nineteen 
patients (61.3%) had more than three metastatic sites. All 
patients had been previously treated with ATCV. They 
received the MM regimen as the 5–8th line (median 5) 
treatment (Table 1).
Efficacy
Twenty-three patients (74.2%) were able to continue 
MM until PD was observed. Eight patients (25.8%) ter-
minated MM because of adverse events. They received 
the MM therapy for 1–13 cycles with a median of 4.6 
cycles; CR was not observed. Three patients (9.7%) 
achieved PR. Nine patients (29%) had SD. Three patients 
(9.7%) maintained stability for more than 24 weeks. RR 
and CBR were 9.7 and 19.4%, respectively (Table  2). 
The median TTP was 3.9  months (Fig.  1). TTF was 
3.7 months (Fig. 2).
In luminal-type breast cancer, one patient (4.8%) 
achieved PR, and six patients (28.6%) had SD. In triple 
negative breast cancer, two patients (20%) achieved PR, 
and three patients (30%) had SD.
Safety
Grade 3 or 4 adverse events were seen in 11 patients 
(36%). Grade 3 thrombocytopenia was observed in 
four (12.9%) and Grade 4 in one (3.2%). Grade 3–4 leu-
copenia was observed in four (12.9%) and grade 3–4 
anemia in three (9.7%). No patients had renal toxicity 
resulting from MM. All toxicity was manageable. Dose 
reduction was necessary in seven (22.6%) patients 
mainly due to hematological toxicity (Table  3). Renal 
toxicity, hemolytic uremic syndrome (HUS), was not 
experienced.
Table 1 Patient characteristics (n = 31)
ER estrogen receptor, PR Progesterone receptor, CMF cyclophosphamide, 
methotrexate, and fluorouracil.
Characteristics Patients, n %
Median age (range) 53 (30–75)
 Male 1 3.2
 Female 30 96.8
Performance status
 0 29 93.5
 1 2 6.5
ER/PgR status
 Positive/positive 15 48.4
 Positive/negative 6 19.4
 Negative/negative 10 32.3
No. of metastasis
 Median (range) 3 (1–5)
  1 5 16.1
  2 7 22.6
  3 15 48.4
  4 3 9.7
  5 1 3.2
Site of metastasis
 Lymph node 16 51.6
 Chest wall/skin 3 9.7
 Lung 16 51.6
 Pleura 3 9.7
 Bone 18 58.1
 Liver 18 58.1
 Contra late ral breast 1 3.2
 Muscle 1 3.2
 Peritoneum 2 6.5
No. of prior chemotherapy
 Median (range) 5 (5–8)
  5 19 61.3
  6 9 29.0
  7 1 3.2
  8 2 6.5
Agent used in prior chemotherapy
 CMF 4 12.9
 Anthracycline 31 100
 Taxane 31 100
  Paclitaxel 11 35.5
  Docetaxel 26 83.9
 Capecitabine 31 100
 Vinorelbine 31 100
 S-1 1 3.2
 UFT 3 9.7
 5-DFUR 1 3.2
 Other 1 3.2
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Discussion
MM treatment yielded relatively good results as a late 
line of treatment for metastatic breast cancer even after 
heavy treatment with ATCV.
MMC, which acts as an alkylating agent, has been used 
in combination chemotherapy for various tumors since 
1974. MMC binds to DNA to form an interstrand DNA–
DNA cross-link, which is believed to cause its cytotoxic 
effect. MTX inhibits dihydrofolate reductase, which halts 
the cell cycle by decreasing the synthesis of thymidylate 
and purine nucleotide.
MTX is a folate analog designed to inhibit dihydro-
folate reductase.  Reduced folate is the proximal single 
carbon donor in several reactions involved in the de novo 
synthetic pathways for purine and pyrimidine precursors 
of DNA and RNA that are required for cell proliferation.
While new drugs are currently being developed, sev-
eral conventional drugs such as MMC and MTX have 
become less often administered. But these useful drugs, 
well documented for efficacy and safety, have the poten-
tial to control MBC even after aggressive treatment with 
multiple regimens because MMC and MTX, respec-
tively, have pharmacological mechanisms that are dif-
ferent from previously used anti-cancer drugs. When 
considering the biological function of anti-cancer action 
and cross-resistance, it has been speculated that drugs 
with the same pharmacological mechanisms as previ-
ously used drugs would not have enough power to con-
trol metastatic breast cancer after ATCV. Capecitabine 
and S-1 are known as prodrugs of Fluorouracil (FU) 
and were selectively activated by tumor cells enough to 
exert cytotoxic activity. Although they may seem to be 
newly administered drugs, fluorouracil derivatives such 
as FU have already been used with anthracycline regi-
mens such as CAF (Cyclophosphamide, Adriamycin, and 
FU) or CEF (Cyclophosphamide, Epirubicin, and FU) 
in most MBC patients. Therefore, it is supposed that in 
some cases, resistance to FU might have been established 
before administration of capecitabine and S-1.
Vinorelbine binds to tubulin, inhibiting tubulin polym-
erization into microtubules. Spindle formation leads to 
apoptosis of cancer cells. Vinorelbine’s mitotic micro-
tubule-inhibiting activity correlates with its antitumor 
efficacy (Toi et al. 2005). Eribulin, which is a non-taxane 
inhibitor of microtubule used as monotherapy (Cortes 
et  al. 2011), binds to the vinca domain of tubulin and 
inhibits polymerization of tubulin and assembly of micro-
tubules. In vinorelbine and eribulin treatment, inhibition 
of mitotic spindle assembly leads to cell cycle arrest at 
the G2/M phase. For eribulin, although the target points 
Table 2 Response rate (n = 31)
Response n %
Complete response 0 0
Partial response 3 9.7
Stable disease 6 19.4
Long stable disease 3 9.7
Progressive disease 19 61.3
Objective response rate 3 9.7










Fig. 1 Kaplan–Meier time to progression (TTP) curve. Median TTP 










Fig. 2 Kaplan–Meier time to failure (TTF) curve. Median TTF was 
3.7 months (95% CI 2.9–4.5) (n = 31).
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are different respectively, the target molecule itself is the 
same as in taxane and vinorelbine (Saji 2013; Andreopou-
lou and Sparano 2013).
MM therapy has a mechanism potentially different 
from other drugs previously used. In addition, combi-
nation chemotherapy has the potential to show clinical 
therapeutic efficacy compared to single-drug therapy 
(Andreopoulou and Sparano 2013).
As mentioned in the introduction, MM was effective 
for 24% of the MBC patients treated with anthracycline 
and taxane. The median TTP was 4.8 months when MM 
was used as third-line therapy (Tanabe et al. 2009).
There are studies reporting the clinical efficacy of treat-
ments including MMC and MTX. In a combination of 
MMC, MTX, and VP-16 (VMM), the response rate was 
31%, the clinical benefit rate 47%, the median disease-sta-
bilization duration was 9.1 months, and the median PFS 
was 4.2  months (Aldabbagh 2009). Combination treat-
ment with mitoxantrone, MMC, and MTX (MMM) was 
reported to be as effective as CMF. MMM achieved an 
objective response (51%) comparable to that with CMF 
(60%). Overall median survival was 16 months for MMM 
and 12  months for CMF (Jodrell et  al. 1991). However, 
when cardiac toxicity is considered, administration of 
mitoxantrone cannot be recommended after treatment 
with anthracycline.
The clinical results in these studies support that MM 
shows strong potential as a treatment for MBC. Moreo-
ver, MM might be more effective than monotherapies 
such as capecitabine, vinorelbine, and eribulin (Andreo-
poulou and Sparano 2013).
Treatments for primary breast cancer as well as MBC 
are selected depending on the expression patterns of 
ER, PgR, and HER2. In luminal-type breast cancer, we 
have several choices of endocrine therapy such as selec-
tive estrogen receptor modulators, selective estrogen 
receptor down-regulators and aromatase inhibitors. In 
HER2 positive type breast cancer, we usually use anti-
HER2 target therapy such as trastuzumab, lapatinib, 
pertuzumab with cytotoxic agents, or hormonal treat-
ment. However, there is no promising treatment that is 
effective for triple negative (TN) breast cancer, defined 
as ER negative, PgR negative, and HER2 negative. There-
fore, it is important to develop a variety of treatments 
to increase the choices of chemotherapy with different 
molecular mechanisms.
In our study, 10 patients were TN. Two out of the 10 
had PR, 1 showed long SD, 2 had SD, and the median 
TTF was 4.4  months. Although it was a small number, 
CBR was 30%. On efficacy of eribulin as the third-line 
therapy in 22 TN patients, PFS was 1.8 months and RR 
was 13.8% (Aogi et al. 2012). Eribulin as 1st line therapy, 
12 of TN patients were treated, RR was 16.7% CBR was 
25%, respectively (McIntyre et  al. 2014). Although our 
report was retrospective  one, the results deserve atten-
tion in that all patients were pretreated with ATCV and 
MM was administered later than the fifth line. We found 
no report dealing with chemotherapy for patients with 
metastatic breast cancer, all of whom had been pretreated 
with four regimens of ATCV. Based on our results, MM 
is a potential choice of treatment as fifth-line therapy for 
MBC pretreated with ATCV.
Jia et al. developed new drug delivery systems of MTX 
and MMC loaded PEGylated chitosan nanoparticles (CS-
NPs), which coordinate the early phase targeting effect 
with the late-phase anticancer effect (Jia et  al. 2014). 
The (MTX + MMC)-PEG-CS-NPs exhibited concentra-
tion- and time-dependent cytotoxicity. Jia et  al. showed 
that codelivery of MTX and MMC suppresses tumor 
cell growth to a greater extent than the delivery of either 
drug alone, indicating a synergistic effect. Synergizing the 
therapeutic index might be effective for patients to maxi-
mize the therapeutic effects of MMC while minimizing 
its toxicity. These encouraging data support our results.
Table 3 Toxicity, patient’s number (n = 31)
G1-4 CTCAE grade 1–4.
Toxicity G1 % G2 % G3 % G4 %
Thrombocytopenia 5 16.1 1 3.2 4 12.9 1 3.2
Leucopenia 3 9.7 7 22.6 2 6.5 2 6.5
Anemia 9 29.0 5 16.1 1 3.2 2 6.5
AST/ALT elevation 4 12.9 1 3.2 2 6.5 0 0
Anorexia 0 0.0 3 9.7 1 3.2 0 0
Neuropathy 2 6.5 4 12.9 1 3.2 0 0
Nausea 2 6.5 3 9.7 0 0 0 0
Vomiting 3 9.7 1 3.2 0 0 0 0
Constipation 4 12.9 0 0 0 0 0 0
Diarrhea 5 16.1 0 0 0 0 0 0
Page 6 of 6Fukuda et al. SpringerPlus  (2015) 4:376 
Conclusion
MM treatment may be both effective and tolerable for 
heavily treated patients with good performance status.
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